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Inﬂammation
MacrophageThemitochondrial citrate–malate exchanger (CIC), a known target of acetylation, is up-regulated in activated im-
mune cells and plays a key role in the production of inﬂammatory mediators. However, the role of acetylation in
CIC activity is elusive. We show that CIC is acetylated in activated primary human macrophages and U937 cells
and the level of acetylation is higher in glucose-deprived compared to normal glucose medium. Acetylation en-
hances CIC transport activity, leading to a higher citrate efﬂux from mitochondria in exchange with malate. Cy-
tosolic citrate levels do not increase upon activation of cells grown in deprived compared to normal glucose
media, indicating that citrate, transported from mitochondria at higher rates from acetylated CIC, is consumed
at higher rates. Malate levels in the cytosol are lower in activated cells grown in glucose-deprived compared to
normal glucose medium, indicating that this TCA intermediate is rapidly recycled back into the cytosol where
it is used by the malic enzyme. Additionally, in activated cells CIC inhibition increases the NADP+/NADPH ratio
in glucose-deprived cells; this ratio is unchanged in glucose-rich grown cells due to the activity of the pentose
phosphate pathway. Consistently, the NADPH-producing isocitrate dehydrogenase level is higher in activated
glucose-deprived as compared to glucose rich cells. These results demonstrate that, in the absence of glucose, ac-
tivatedmacrophages increase CIC acetylation to enhance citrate efﬂux frommitochondria not only to produce in-
ﬂammatorymediators but also tomeet the NADPH demand through the actions of isocitrate dehydrogenase and
malic enzyme.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Among themechanisms regulating cell metabolism, reversible acet-
ylation of the ε-amino group of internal lysine (acetylation) has
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tegna),function of non-histone proteins such as transcription factors and met-
abolic enzymes [1]. In particular acetylation/deacetylation of mitochon-
drial proteins most likely represents one mechanism by which
mitochondrial functions are tailored to meet the demand of metabolic
challenges [2]. Novelﬁndings fromacetylome studies [1] have identiﬁed
as targets of acetylation proteins belonging to themitochondrial carrier
family (MCF), which transport important metabolites into and out of
mitochondria [3,4]. One of these targets is themitochondrial citrate car-
rier (CIC), which catalyses the export of citrate from the mitochondrial
matrix in exchange for cytosolic malate [5–7]. This transporter is essen-
tial for fatty acid biosynthesis because citrate in the cytosol is cleaved to
acetyl-CoA and oxaloacetate by citrate lyase. Acetyl-CoA is directly used
for fatty acid synthesis, and oxaloacetate produces NADPHplusH+ (also
necessary for fatty acid production) via malate dehydrogenase and
malic enzyme [8]. However, the role of acetylation on this protein func-
tion is not known. Recently it has been shown that CIC expression
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of inﬂammatorymediators [9,10]. This seminalﬁnding is crucial to under-
standmacrophagemetabolism, although further information on how this
carrier activity is modulated during the complex metabolic activation of
macrophages is lacking. In the present studywe show that CIC is acetylat-
ed in activated humanmacrophages and histiocytoma U937 cells and the
level of acetylation is dependent on the available carbon sources, increas-
ing when glucose is absent. We provide evidence that CIC acetylation in-
creases citrate efﬂux in exchange with malate, to respond to the
increasing cellular NAPDH demand. Lack of glucose diverts NADPH pro-
duction from the pentose phosphate pathway (PPP) to themalic enzyme
[11] and NADP+-isocitrate dehydrogenase (IDH1), making NADPH avail-
ability strictly dependent on citrate efﬂux. Activated cells respond to this
request by increasing the acetylation of CIC, which results in a net in-
crease of cytosolic citrate. Thismechanism is essential in a lowglucose en-
vironment, in which immune cells need to reprogram metabolism to
sustain the many cellular functions typical of their activation.
2. Materials and methods
2.1. Cell growth
Human blood samples were obtained from healthy individuals at
Thomas Jefferson University Hospital under an Institutional Review
Board approved protocol. Human monocytes were isolated by using
CD14 MicroBeads (Miltenyi Biotec) [12]. Monocytes were seeded in
RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum,
2 mM l-glutamine, 100 units of penicillin and 100 μg/mL streptomycin
at 37 °C in 5% CO2 at a concentration of 6 × 105 cells/mL. Differentiation
was carried out as previously described [9]. Histiocytoma U937 cells
(ICLC HTL 94002-Interlab Cell Line Collection) were cultured as de-
scribed above. Right before activation both primary macrophages and
U937 cells were transferred into a either glucose or glucose-free medi-
um and activated with 2 μg/mL bacterial LPS (Sigma) or with 5 ng/mL
of TNFα and 10 ng/mL of IFNγ (Immunotools) for 24 h [9,10]. As acety-
lation control, humanmacrophages incubated in glucose or glucose-less
medium were treated with the deacetylase inhibitor 10 mM nicotin-
amide alone (NAM, Sigma) for 24 h [13]. CIC was inhibited in U937
cells by adding 1 μM of the speciﬁc CIC inhibitor 4-chloro-3-[(3-
nitrophenyl)amino]sulfonyl benzoic acid (CNSB, Millipore) [6] 1 h
before activation.
2.2. Immunoprecipitation and Western blotting of CIC carrier
For CIC immunoprecipitation cell pellets (5 × 106 cells) were resus-
pended in 1 mL of denaturing lysis buffer (1% SDS, 5 mM EDTA, 50 mM
Tris–HCI, pH 7.4) and the lysates centrifuged for 15 min at 20,000 ×g.
After the supernatants were diluted with 50 mM Tris–HCl, 100 mM
NaCl and 1% Triton X-100, rabbit antiserum directed against CIC carrier
was added, and the mixture was incubated with shaking for 1 h at 4 °C.
Then 75 μL Protein G microbeads (Miltenyi Biotech) were added; after
mixing, samples were incubated with shaking for 30 min at 4 °C. For
magnetic immunoseparation beads were incubated with 20 μL of 1×
SDS-PAGE sample buffer (1% SDS, 50 mM Tris–HCl pH 6.8, 50 mM
DTT, 10% glycerol, 0.005% bromophenol blue). Elution of the
immunoprecipitated protein was carried out by adding a further 30 μL
of elution buffer.
For SDS-PAGE of immunoprecipitates, eluted proteinswere incubat-
ed at 95 °C for 5 min. Then the same amount of eluted proteins from
each sample was loaded in two different lanes of a continuous 12%
SDS PAGE. The electrophoresed proteins were blotted on a nitrocellu-
lose membrane and probed with anti-acetyl-lysine antibody (Santa
Cruz Biotechnology) or CIC antibody. The immunoprecipitated proteins
were visualized through the immunoreaction of the goat anti-rabbit
secondary antibody detected by the Immobilon Western chemilumi-
nescent kit (Millipore) and normalized against β-actin protein levels.2.3. Construction of expression vector harboring SIRT3 complete coding
sequence (CDS) and transient transfection in U937 cells
1 μg of human liver total RNA (AM7960, Life Technologies) was re-
verse transcribed with GeneAmp RNA PCR core kit (Applied Biosystem)
as described previously [14]. The full-length coding region of the human
SIRT3 (GenBank accession number NM_012239.5) was ampliﬁed from
Liver cDNA using the iProof High Fidelity DNA Polymerase (Bio-Rad),
GC Buffer, dimethyl sulfoxide (DMSO), dNTPs, a 5′-primer (5′ CAGGAA
TTCATGGCGTTCTGGGGTTGGCGCG 3′) and a 3′-primer (5′ CGACTCGA
GCTATTTGTCTGGTCCATCAAGCTT 3′) in a ﬁnal volume of 50 μL
(Infantino et al., 2013). The fragment was then cloned into
pcDNA3.1(+) vector (Invitrogen) in the sense orientation. The ﬁdelity
of the ﬁnal human SIRT3 insert in pcDNA3.1(+) plasmid was veriﬁed
by DNA sequencing using BigDye Terminator Kit (Applied Biosystems).
U937 cells were transfected with the pcDNA3.1(+) vector contain-
ing the target SIRT3 DNA sequence by FuGENEHD Transfection Reagent
(PROMEGA) according to themanufacturer's instructions. In brief, U937
cells were plated the day of transfection at a density of 1 × 107 cells
into a T-150 ﬂask and grown in 47 mL of RPMI medium with 10% FBS
and 1% penicillin/streptomycin. The mixture of plasmid (24 μg) and
transfection reagent (144 μL) in Opti-MEM medium without serum
(Recommended Reagent:DNA ratio for U937 cells is 6:1) was added to
the culture and the cells were incubated for 48 h. Two days later,
transfected cells were used in the experiments. The transfection efﬁ-
ciency was analyzed by immunoblotting with anti-sirt3 antibody
(SantaCruz Biotechnology). Where indicated transfected cells, were
also treated with nicotinamide (NAM, Sigma) for 24 h at the concentra-
tion of 10 mM.2.4. Reconstitution of solubilized mitochondria and transport measurements
Mitochondria (0.41 mg/mL), isolated as described [15] were sol-
ubilized in 3% Triton X-114, 50 mM NaCl, 1 mM EDTA, 10 mM
HEPES pH 7.2. After 20 min at 0 °C, the mixture was spun at
100,000 ×g for 10 min. The supernatant (extract) was reconstituted
into phospholipid vesicles (liposomes) by cyclic removal of the de-
tergent using a hydrophobic column [16]. The composition of the ini-
tial mixture used for reconstitution was: 70 μL of mitochondrial
extract, 57 μL of 10% Triton X-114, 100 μL of 10% phospholipids in
the form of sonicated liposomes [17], 10 mM citrate, 0.6 mg
cardiolipin, 20 mM HEPES, pH 7.2, and water to a ﬁnal volume of
700 μL. These components were mixed thoroughly, and the mixture
was recycled 13 times through an Amberlite column (3.2 × 0.5 cm)
pre-equilibrated with the same buffer and the same concentration
of the substrate (except where otherwise indicated) present in the
reconstitution mixture. External substrate was removed from pro-
teoliposomes on a Sephadex G-75 column preequilibrated with a
buffer containing 50 mM NaCl and 10 mM Hepes, pH 7.2. Transport
at 25 °C was started by adding 1 mM [14C]citrate to the proteolipo-
somes and terminated by the addition of 20mMpyridoxal 5′-phosphate,
an inhibitor of several mitochondrial carriers [18–20]. In controls,
carrier-mediated transport was inhibited by addition of pyridoxal phos-
phate togetherwith the labeled substrate [21]. The external radioactivity
was removed on Sephadex G-75 and the internal radioactivity wasmea-
sured. The transport activity was the difference between experimental
and control values.
Transport assays with isolated mitochondria were performed as de-
scribed [22] with some modiﬁcations. Brieﬂy, mitochondria (0.6 mg)
were incubated in a buffer containing 100 mM KCl, 20 mM HEPES,
pH 7.0, and 2 μg of rotenone. Transport at 9 °C was performed adding
1 mM of [14C]citrate to mitochondria and terminated after 15 s by
adding 20 mM BTA (benzene-1,2,3-tricarboxylate). Mitochondria
were pelleted, suspended with water and extracted with HClO4; and
the extracts were used for scintillation counting of 14C.
Fig. 1. Immunoprecipitation of CIC from human macrophages. (a) SDS-PAGE of the
immunoprecipitated protein sample shows the target protein at 33 kDa (the CIC protein)
and a 55 kDa band, which is the denatured heavy antibody chain. (b) SDS-PAGE of the CIC
antibody shows the band at 55 kDa. (c) Western blotting and immunostaining of mito-
chondrial extracts with the CIC antibody indicate a major band at 33 kDa.
Fig. 2. Acetylation levels of CIC in activated human macrophages in high glucose or
glucose-free medium. CIC was immunoprecipitated from primary human monocytes-
derived macrophages, treated for 24 h with LPS, TNFα/IFNγ or NAM in (a) glucose-rich
or (b) glucose-free conditions, and probed with anti-CIC and anti-acetyl-lysine antibody.
(c) CIC acetylation levels in glucose-rich (white bars) or glucose-free (black bars)medium
are normalized to total CIC protein amount and are reported as AcCIC/CIC means± S.E.M.
of six independent experiments. Signiﬁcant differences of the CIC acetylation levels in cells
treated in glucose-free compared to glucose rich medium (*p b 0.05, one-way ANOVA)
and NAM compared to LPS or TNFα/IFNγ are indicated (#p b 0.05, one-way ANOVA).
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Modeller was used to calculate three dimensional structural models
of human CIC coded by the SLC25A1 gene using the structure of the
bovine BtAAC1 (protein data bank accession code: 1okc) as template
for the comparative modeling as previously described for CIC and
other mitochondrial carriers [4,23]. For citrate docking analysis, citrate
ligand was docked into the predicted binding sites using Autodock
1.5.2 as previously described [23]. Experimentally detected post-
translational modiﬁcations of citrate carrier were recovered from
the PhosphoSitePlus resource (http://www.phosphosite.org). The
acetylation of K97 was introduced in the 3D protein model with the
Molefacture tool (http://www.ks.uiuc.edu/Research/vmd/) as previously
described for other carriers [4].
2.6. Liquid chromatography tandemmass spectrometry analysis (LC-MS/MS)
of metabolites in U937 cells
For mass spectrometry analysis fast separation of post-
mitochondrial supernatant (PMS) was achieved as described [15]. Vol-
umes corresponding to 2mgof proteins from PMSwere extracted as in-
dicated [15,24–27]. A Quattro Premier mass spectrometer interfaced
with an Acquity UPLC system (Waters) was used for LC-MS/MS analysis
as described [24,26–29]. Calibration curveswere established using stan-
dards, processed under the same conditions as the samples, at ﬁve con-
centrations. The best ﬁt was determined using regression analysis of the
peak analyte area. The multiple reaction monitoring transitions in the
positive ion mode were m/z 744.06 N 507.83 for NADP+ and m/z
746.02 N 729.00 for NADPH. TheMRM transitionsmonitored in the neg-
ative ion mode for TCA intermediates werem/z 190.95 N 110.89 for cit-
rate andm/z 132.95 N 115.20 for malate. The ﬂow rate was 0.3 mL/min.
2.7. Real-time PCR
Total RNA was extracted from 1 × 106 U937 cells activated in the
presence or absence of glucose and reverse transcribed as described
[30]. Real-time PCR was performed as described [31,32]. Taq-man
probes for human IDH1, and human β-actin were purchased from
Applied Biosystems. All transcript levels were normalized against
the β-actin expression level.
3. Results
3.1. CIC acetylation in differentiated and LPS- or TNFα/IFNγ-treated human
macrophages
Since CIC is known to be acetylated in humans [1] we investigated
whether CIC is a target of acetylation in primary human monocyte-de-
rived macrophages. We ﬁrst immunoprecipitated the CIC carrier from
macrophages as described in the Methods section. Immunoprecipitated
samples displayed a major band at 33 kDa corresponding to the carrier
molecular weight (Fig. 1). The level of CIC acetylation was tested in ac-
tivated macrophages in the presence (Fig. 2a) or absence of glucose
(Fig. 2b). Both sets of sampleswere processed for CIC immunoprecipita-
tion and Western blotting exactly in the same way, and the levels of
acetylated CIC normalized to total CIC (AcCIC/CIC ratio) were evaluated.
In glucose-rich medium LPS or TNFα/IFNγ activation induced a small
decrease in AcCIC/CIC ratio, due to the increase of CIC expression with-
out a signiﬁcant change in the acetylation levels. Switching control cells
from glucose-rich to glucose-less medium produced a slight increase in
AcCIC/CIC ratio (Fig. 2b and c). LPS or TNFα/IFNγ-activated cells grown
without glucose displayed a 52 and 70% increase, respectively, in
AcCIC/CIC ratio compared to the corresponding activated cells in
glucose-rich medium (Fig. 2c). As a positive control, cells were treated
with the deacetylase inhibitor NAM (in the absence of LPS or TNFα/
Fig. 4. Functional characterization of CIC from mitochondria of U937 cells grown in the
presence or absence of glucose. The uptake rate of [14C] citrate was measured by adding
1 mM of [14C] citrate to proteoliposomes reconstituted with mitochondrial extracts from
U937 cells activated with TNFα/IFNγ in normal or glucose-deprived medium in the pres-
ence or absence of internal citrate (uniport). Themeans and S.E.M. from four independent
experiments are shown (*p b 0.01, one-way ANOVA).
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in both glucose grown- or glucose deprived-cells (Fig. 2c).
3.2. CIC acetylation in TNFα/IFNγ-activated U937 cells
To obtain insight into the role of the acetylation with respect to the
citrate/malate exchange features of CIC we used the U937 histiocytic
lymphoma cells, a model cell line that matures in response to a number
of soluble stimuli, adopting the morphology and characteristics of
monocytes/macrophages. We used the combination of TNFα and IFNγ
as activatory stimulus since it produced a similar or more prominent ef-
fect than LPS on CIC acetylation in activated macrophages (Fig. 2). The
level of CIC acetylation was tested in activated U937 cells in the pres-
ence (Fig. 3a) or absence of glucose (Fig. 3b). Switching control cells
from glucose-rich to glucose-free medium did not produce any signiﬁ-
cant change in Ac-CIC/CIC ratio (Fig. 3c). TNFα/IFNγ-activated cells
grown in the absence of glucose displayed a 50% increase in Ac-
CIC/CIC ratio compared to similarly activated cells grown in glucose-
rich medium (Fig. 3c).
3.3. CIC transport activity in TNFα/IFNγ-activated U937 cells grown in con-
ditions of glucose rich and deprived medium
We tested the activity of CIC in mitochondrial extracts from U937
cells grown in normal or glucose-free medium as performed for other
mitochondrial carriers [15,33,34]. As shown in Fig. 4 the uptake of radio-
active citrate (normalized to the amount of CIC protein) in liposomes
reconstituted with mitochondrial extract from TNFα/IFNγ-treated
cells grown in the absence of glucose (measured as [14C]citrate/citrate
homoexchange, the distinctive transport of CIC) was markedlyFig. 3. Acetylation levels of CIC in activated U937 cells in high glucose or glucose-free me-
dium. CIC was immunoprecipitated from U937 cells, treated for 24 h with TNFα/IFNγ in
(a) glucose-rich or (b) glucose-deprived conditions, and probed with anti-CIC and anti-
acetyl-lysine antibody. (c) Acetylation levels of CIC normalized to total CIC are reported
as means ± S.E.M. of at least three independent experiments. Signiﬁcant differences of
the CIC acetylation levels in cells treated in glucose-deprived compared to glucose rich
cells are indicated (*p b 0.05, one-way ANOVA).increased as comparedwith those reconstitutedwith themitochondrial
extract from TNFα/IFNγ-treated cells grown in normal medium
(84.0±13.0 versus 42.0±6.0 μmol of citrate/min x g of protein, respec-
tively, p b 0.001). Uptake of [14C]citrate without internal citrate was
negligible in both conditions.
To evaluate whether the acetylation of CIC inﬂuences the Km and/or
the Vmax, the kinetic constants of CIC in liposomes reconstituted with
mitochondrial extracts from TNFα/IFNγ-activated cells grown in the
presence or absence of glucose were determined by measuring the ac-
tivity at varius [14C]citrate concentrations in the presence of a ﬁxed sat-
urating concentration of internal citrate.
The Vmax value of CIC in liposomes reconstitutedwithmitochondrial
extracts from cells activated in glucose-free medium was substantially
higher than that determined in liposomes reconstitutedwithmitochon-
drial extracts from activated cells in normalmedium (89.5±19.6 μmol/
min ×g of protein versus 37.0 ± 5.4 μmol/min ×g of protein). By con-
trast, the Km values of CIC for citrate were similar in both growth condi-
tions (60.0 ± 5.1 versus 63.0 ± 7.1 μM, p b 0.01). Therefore CIC
acetylation increases the maximal activity of the transport without
changing its Km for citrate.
3.4. CIC acetylation in resting and SIRT3-overexpressing U937 cells
To providemore evidence in favor of the role of CIC acetylation on its
transport activity, the effect of NAM on CIC acetylation and transport
was tested in both control and pcDNA3-SIRT3 overexpressing U937
cells grown in glucose rich medium but in the absence of LPS or
TNFα/IFNγ. The AcCIC/CIC ratios signiﬁcantly increased in NAM treated
compared to untreated U937 cells (Fig. 5a). Furthermore, NAM treated
pcDNA3-SIRT3 cells displayed signiﬁcantly higher AcCIC/CIC ratios com-
pared to SIRT3-overexpressing cells (Fig. 5b). CIC protein levels were
unchanged in both cases (Fig. 5a-b).
The effect of NAMon CIC transport activity inmitochondrial extracts
from control and pcDNA3-SIRT3 overexpressing U937 cells was then
evaluated.With NAM control cell-derivedmitochondria exhibited a sig-
niﬁcant increase in CIC transport activity compared to untreated cells
(17.33± 0.50 versus 12.90± 1.50 μmol of citrate/min ×g of protein, re-
spectively, p b 0.01) (Fig. 5c). These results parallel the acetylation levels
of CIC measured under the same conditions (Fig. 5a). A greater increase
in CIC activity was observed using mitochondrial extracts from NAM-
treated compared to untreated SIRT3 overexpressing U937 cells
Fig. 5. Functional characterization of acetylated CIC. CICwas immunoprecipitated from control (a) and pcDNA3-SIRT3 transfectedU937 cells (b) in the absence or presence of 10mMNAM
and probedwith anti-CIC and anti-acetyl-lysine antibody. Normalized acetylation levels of CIC are reported asmeans± S.E.M. of three independent experiments. Signiﬁcant differences of
the CIC acetylation levels in NAM-treated compared to control cells and NAM-treated compared to NAM-untreated SIRT3 overexpressing cells are indicated (*p b 0.05, one-way ANOVA).
(c–d) The uptake rate of [14C] citrate was measured by adding 1 mM of [14C] citrate to proteoliposomes reconstituted with mitochondrial extracts from control and NAM treated
(c), pcDNA3-SIRT3 transfected and pcDNA3-SIRT3/NAM-treated resting U937 cells (d) in the presence or absence of internal citrate (uniport). (e) The uptake rate of [14C] citrate was
measured by adding 1mMof [14C] citrate to intact mitochondria isolated from pcDNA3-SIRT3 and NAM-treated pcDNA3-SIRT3 U937 cells. Themeans and S.E.M. from three independent
experiments are shown (*p b 0.01, one-way ANOVA).
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spectively, p b 0.01) (Fig. 5d). All these results parallel the acetylation
levels of CIC measured under the same conditions (Fig. 5b).
To exclude the possibility that acetylation affects the reconstitution
of CIC into liposomes, we measured the transport of radioactive citrate
into intact mitochondria isolated from pcDNA3-SIRT3 transfected cells
treated or untreated with NAM. Also in these experiments the uptake
of [14C]citrate was markedly increased in NAM-treated compared to
NAM-untreated SIRT3 overexpressing cells (50.4 ± 3.2 versus 11.3 ±
2.1 μmol of citrate/min ×g of protein, p b 0.01) (Fig. 5e), indicating
that the increase of CIC transport activity reﬂecting the levels of the car-
rier acetylation is not an artifact linked to the reconstitution procedure
used in the present work.
3.5. Molecular modeling of CIC acetylated in K97
We investigated the inﬂuence of the acetylation of K97, found to be
acetylated in human CIC [1], on citrate binding in order to provide amo-
lecular explanation of the increased Vmax in acetylated cells. K97 is lo-
cated close to residues of the proposed citrate binding site [4,23] and
appears to participate in citrate binding (Fig. 6a-b) together with resi-
dues R282 and R285. The putative acetylation of K97would allow a bet-
ter ﬁtting of the proposed binding region due to the strengthening of
citrate interactions with basic residues R282 and R285. Furthermore,
the acetylation of K97 produces a different network of interactions
among citrate, residues of the proposed binding region and residues of
the matrix gate (m-gate) (Fig. 6a-b).3.6. Citrate andmalate levels in the PMS of TNFα/IFNγ-activated U937 cells
in conditions of glucose-rich versus glucose-deprived medium
To ascertain whether CIC acetylation modiﬁes citrate and malate
levels in the cytosol we measured these metabolites in the PMS of
TNFα/IFNγ-activated compared to resting U937 cells grown in the pres-
ence or absence of glucose.
In glucose-rich medium, cytosolic levels of citrate were signiﬁcant-
ly higher in activated compared to resting U937 cells (Fig. 7a), consis-
tent with the increased CIC gene expression during immune activation
[9,10]. As expected, upon CIC inhibition citrate levels were reduced
almost to the control ones (Fig. 7a). Cytosolic levels of malate were
signiﬁcantly higher in activated- compared to resting-U937 cells
(Fig. 7c), suggesting that, in the presence of glucose, PPP is activated
and malate is not rapidly consumed by the malic enzyme. A further
signiﬁcant increase in cytosolic malate was measured in the presence
of CNSB (Fig. 7c), suggesting that following CIC inhibition, malate can-
not enter mitochondria in exchange with citrate, but is probably
transported back from mitochondria in place of citrate by the
dicarboxylate carrier (DIC).
In glucose-free medium control levels of citrate (Fig. 7b) are lower
compared to the levels of this metabolite measured in glucose-rich me-
dium (Fig. 7a). Citrate did not accumulate in the cytosol of activated-
compared to resting-U937 cells (Fig. 7b) and upon CIC inhibition citrate
levels were more strongly reduced in glucose-free versus glucose-rich
media (Fig. 7b). This indicates that in cells activated in the absence of
glucose citrate is probably being consumed at very high rates. Malate
Fig. 6.Molecular modeling of acetylated CIC at K97. The exploded view of citrate carrier
cavity is reported in grey cartoon representation. Residues of the proposed binding region
(K97, R282, R285) and citrate ligand are reported in sticks representation and indicated by
black labels. Residues forming the matrix gate are reported in gray surf representation. In
panel a is possible to see K97 acetylated. Ionic and H-bond interactions between residues
of the proposed binding region, the citrate ligand and residues of the matrix gate are rep-
resented with dashed lines and black labels.
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resting-U937 cells (Fig. 7d). Activation in the presence of the CIC inhib-
itor reinstated malate levels only to those of the control samples
(Fig. 7d), indicating that malate, under these conditions, is more rapidly
metabolized by themalic enzyme,which is essential for NADPHproduc-
tion in the absence of glucose [35,36].3.7. NADP+/NADPH ratios in the PMS of TNFα/IFNγ-activated U937 cells in
conditions of glucose-rich versus glucose-deprived medium
Since NADPH is an important factor in immune cell activation re-
gardless of the cell growth conditions, its levels may be dependent on
CIC activity when glucose is not available. To determine if this was the
case we quantiﬁed the levels of NADPH and NADP+ in TNFα/IFNγ-
activated compared to resting U937 cells grown in the presence or ab-
sence of the CIC inhibitor CNSB in conditions supporting different levels
of CIC acetylation.Upon TNFα/IFNγ activation in the presence of glucose
NADP+/NADPH ratios were decreased compared to resting cells
(Fig. 8a). A similar decrease was displayed by activated cells treated
with the CIC inhibitor (Fig. 8a). In the absence of glucose availability,
the NADP+/NADPH control ratio (Fig. 8b) was higher compared to
that measured in high glucose (see Fig. 8a). Furthermore, the NADP+/
NADPH ratio was signiﬁcantly elevated by activating the cells and
even higherwhen the activated cells were treatedwith the CIC inhibitor
(Fig. 8b), indicating that the contribution of citrate transport frommito-
chondria is important for NADPH synthesis. In all cases the total amount
of the phosphorylated pyrimidine coenzymes (NADP++NADPH) was
similar (Fig. 8c–d).3.8. Isocitrate dehydrogenase expression levels in TNFα/IFNγ-activated
U937 cells in conditions of glucose-rich versus glucose-deprived medium
To ascertain whether alternative pathways to produce NADPH are
induced in activated U937 cells grown in free versus rich glucose medi-
um, we assessed mRNA levels of IDH1, a NADP+-dependent citrate to
oxoglutarate converting enzyme that is known to be suppressed in
cells undergoing a pro inﬂammatory stimuli [37]. Compared to IDH1
mRNA levels in control, unstimulated cells, a decrease of about 4-fold
was observed in U937 cells activated in glucose-rich medium (Fig. 9a).
Surprisingly, an increase of approximately 1.6-fold of IDH1 mRNA was
observed in U937 cells activated in glucose-free medium as compared
to similarly cultured control cells (Fig. 9b).
4. Discussion
Among the carrier proteins present in the inner membrane of mito-
chondria, the citrate transport system (CIC) plays an important role in
fatty acid synthesis, gluconeogenesis, and the transfer of reducing
equivalents across the inner mitochondrial membrane. According to
previously published data on the protein isolated from rat liver and
reconstituted into liposomes [6,7,38] CIC catalyzes the efﬂux of citrate,
together with a proton, from the matrix to the cytosol in an
electroneutral exchange for another tricarboxylate-H+,malate, or phos-
phoenolpyruvate [39]. The proposedmechanismof transport is sequen-
tial [39], which implies the obligatory presence of a counter substrate
for citrate efﬂux. The citrate/malate antiport fulﬁlls importantmetabolic
demands [40]. Citrate is a key substrate for the generation of energy and
a modulator of several enzymatic activities. In the mitochondria citrate
is oxidized via the Krebs cycle and Oxidative Phosphorylation
(OXPHOS). In the cytoplasm citrate inhibits glycolysis while supporting
lipid synthesis and the reduction of NADP+ [41,42]. Recent data have
shown that CIC expression is increased in INS-1 cells challengedwith in-
sulin [43], in cancer [44,45] and in activated macrophages during in-
ﬂammation [9].
Extensive reports support the concept that immune cells are
adapted to use different nutrient sources [46]. It is known that glucose
contributes to 60% of an immune cell's energy needs, the remaining
40% being satisﬁed by glutamine [11]. Macrophages consume very
high amounts of glucose although only 10% is oxidized [35], whereas
glutamine is oxidized at high rates [11,35]. Both energy substrates can
produce high amounts of NADPH through different NADPH-generating
pathways. When glutamine is used to produce new amino acids in pe-
riods of active synthesis and secretion, glucose is diverted to the PPP
for NADPH synthesis [11]. Conversely, a considerable proportion of
NADPH is produced via glutamine metabolism when glucose 6-
phosphate dehydrogenase is inhibited in macrophages by adrenaline
[35], or during periods of active pinocytosis and phagocytosis, in
which glucose carbon may be diverted toward lipid synthesis [11].
The inﬂammatory response is nutritionally challenged in conditions of
low glucose availability, as the cellular NADPH demand cannot be
sustained by the PPP. Alternative sources of NADPH require high cyto-
solic levels of citrate. Indeed this TCA intermediate can be converted
to malate, which is substrate of the NADPH-producing malic enzyme,
or can be direct substrate of the NADP+-dependent isocitrate dehydro-
genase, although its expression has been shown to be suppressed under
pro inﬂammatory challenge [37]. In both cases NADPH production be-
comes more dependent on citrate efﬂux from mitochondria.
Our data demonstrate that in conditions of glucose deprivation cells
respond to activation with proinﬂammatory cytokines by promoting a
novel mechanism of post-translational control of CIC activity that inﬂu-
ences the rate of citrate efﬂux. CIC is more acetylated in activated mac-
rophages grown in the absence of glucose compared to those grown in
normal glucose. Acetylation increases the rate of citrate efﬂux frommi-
tochondria in exchange for cytosolic malate thereby assuring NADPH
production. Indeed in activated cells treated with the CIC inhibitor the
Fig. 7. Citrate andmalate levels in PMS of U937 activated cells. U937 cells grown in glucose (a and c) or glucose-free (b and d)mediumwere activatedwith TNFα/IFNγ in the presence or
absence of CNSB, and PMSwere collected. Citrate andmalate levels are reported asmeans± S.E.M. of at least four independent experiments. The signiﬁcance of the difference among the
citrate or malate levels of activated compared to control cells are indicated (*p b 0.05, one-way ANOVA). The signiﬁcance of the difference among the citrate and malate levels of CNSB-
treated compared to those in activated cells not treated with CNSB is indicated. (#p b 0.05, one-way ANOVA).
735E.M. Palmieri et al. / Biochimica et Biophysica Acta 1847 (2015) 729–738NADP+/NADPH ratio increases in glucose-free but not in glucose-rich
medium. This indicates that in absence of glucose activated cells cannot
rely on the PPP for NADPH production and become more closelyFig. 8. NADP+/NADPH ratios and (NADP++NADPH) total amount in the PMS of U937 activate
tivatedwith TNFα/IFNγ in thepresence or absence of CNSBand PMSwere collected. NADP+/NA
independent experiments. The signiﬁcance of the difference among the NADP+/NADPH levels
niﬁcance of the difference among the NADP+/NADPH levels of CNSB-treated compared to thosdependent on CIC activity for NADPH production. Activated cells in
glucose-freemedium contain lower levels of malate in the cytosol com-
pared to those activated in glucose richmedium and CIC inhibition doesd cells. U937 cells grown in glucose (a and c) or glucose-free (b and d) mediumwere ac-
DPH ratios and the sums ofNADP++NADPHare reported asmeans±S.E.M. of at least four
of activated compared to control cells are indicated (*p b 0.05, one-way ANOVA). The sig-
e in activated cells non treated with CNSB is indicated. (#p b 0.05, one-way ANOVA).
Fig. 9. IDH1 expression in TNFα/IFNγ activated U937 cells. (a) Total RNA from TNFα/IFNγ
activated monocytes was used to quantify IDH1 mRNA in the presence (a) or absence
(b) of glucose. Means ± S.E.M. of three duplicate independent experiments are shown.
Differences between samples and relative controls were signiﬁcant (*p b 0.05, one-way
ANOVA).
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the absence of glucose cytosolic malate is rapidly consumed by the
malic enzyme to produce NADPH. In addition, IDH1 expression levels
are increased in U937 cells activated in the absence of glucose, indicat-
ing that the citrate conversion to α-oxoglutarate represents an addi-
tional route utilized by immune cells to exploit increased citrate efﬂux
for NADPH production. We propose a model in which acetylation/
deacetylation equilibrium of CIC represents a cellular mechanism by
which the exchange activity of the carrier is rapidly tuned to meet
NADPH demand (Fig. 10). In conditions of high glucose levels, activated
cells can rely on the PPP to produce NADPH. CIC protein levels are in-
creased, but the levels of acetylated carrier are low (Fig. 10a). During a
sustained inﬂammatory response orwith limiting availability of glucose
as nutrient, activated cells tune CIC exchange activity by increasing its
acetylation (Fig.10b). Thismodiﬁcation produces a rapid efﬂux of citrate
in exchange with malate, which is rapidly transported back into theFig. 10. Role of CIC acetylation in inﬂammation. During activation of the inﬂammatory respons
presence of glucose, activated immune cells produce NADPHmainly through the pentose phosp
citrate into the cytosol coupledwithmitochondrial uptake ofmalate. (b) In the absence of gluco
dent on cytosolic citrate. Increase of CIC acetylation increases efﬂux of citrate in exchangewithm
be converted to pyruvate. The increased cytosolic amount of citrate can then enter the IDH1 co
fatty acid synthesis. Other abbreviations used: PYC, pyruvate carrier; PIC phosphate carrier; Pi, i
glutamate dehydrogenase; AcK, acetylated lysine; CL, citrate lyase, IDH1, isocitrate dehydrogencytosol in exchange with phosphate, probably by the dicarboxylate car-
rier (DIC) [47], to be rapidly converted to pyruvate by themalic enzyme.
In this way the increased citrate/malate exchange driven by acetylation
results in a net increase in the efﬂux of citrate in exchange with phos-
phate, which re-equilibrates across the inner mitochondrial membrane
by recycling on its own transporter [48,49]. The increased net efﬂux of
citrate can simultaneously provide both acetyl-CoA for fatty acid bio-
synthesis through the ATP-citrate lyase andNADPHnecessary to sustain
cell functions through IDH1 and malic enzyme (Fig.10b).
K97 is the CIC lysine residue found acetylated in proteomics
analyses [1] (http://www.phosphosite.org/proteinAction.do?id=
7150&showAllSites=true) putatively directly involved in interac-
tions with citrate. We proposed that its acetylation might improve
citrate ﬁtting at the CIC substrate-binding area [4,23]. The replace-
ment of the longer ionic bond with the shorter H-bond does not af-
fect conformational changes and allows a more efﬁcient substrate
ﬁtting within the CIC binding site, even favoring a faster uptake
and translocation of the CIC substrates without affecting their Km.
It could also be speculated that the acetylation of CIC suggests the
presence of mitochondrial acetyl-transferases that can acetylate
citrate carrier [50], even if it has also been hypothesized that mito-
chondrial acetylation could have evolved as a nonenzymatic phe-
nomenon [51-53].
In conclusion,we have provided evidence that themitochondrial CIC
plays an important role in sustaining macrophage function during acti-
vation not only for fatty acid (prostaglandins) biosynthesis but also for
NADPH production. Acetylation of CIC is a key event increasing the ac-
tivity of CIC and thereby enhancing the efﬂux of citrate frommitochon-
dria under speciﬁc metabolic conditions. This newly discovered
mechanism is likely to be fundamental for macrophage activation,
explaining how these cells canmaintain the inﬂammatorymechanisms,
when subjected to rapidly changing energy sources in the context of in-
fection or other immune stimuli.
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